



ICOS CORPORATION
22021 20th Avenue S.E.
Bothell, WA 98021
425.485.1900

February 4, 2000

FOOD AND DRUG ADMINISTRATION
Dockets Management Branch HFA-305
12420 Parklawn Dr., Room 1-23
Rockville, MD 20857
Attn: Docket Number 95S-0158

Subject: BB-IND 7371
Protocol AHS02: Disclosure of Study Results, and Additional Community
Consultation Documentation

To Dockets Management Branch:

Reference is made to our Investigational New Drug Application for Humanized Monoclonal Antibody Hu23F2G for Hemorrhagic Shock, BB-IND 7371, which was originally submitted to the FDA Office of Therapeutics Research and Review on October 28, 1997. We also refer to:

- i) Protocol AHS02, entitled "Phase 2B Safety and Efficacy Study of Hu23F2G in Subjects with Hemorrhagic Shock," which was included in the original submission.
- ii) The guidelines described in 21 CFR §312.54(a) which require that Institutional Review Board (IRB) information concerning public disclosure be submitted to Docket 95S-0158, for clinical investigations involving an exemption from informed consent under 21 CFR §50.24.

The purpose of this submission is to provide documentation (21 CFR §50.24(a)(7)(iii)) concerning public disclosure following completion of Protocol AHS02. Individual site's IRBs have approved the ads included in this submission to apprise the communities and researchers of the completed study. Each ad includes demographic characteristics of the research population and the study results.

Listed below are two of the IRBs which governed sites that conducted Protocol AHS02. Copies of advertisements for disclosure of study results as approved by these IRBs are included in this submission.

Henry Ford Hospital Human Rights Committee (Institutional Review Board)
Henry Ford Hospital
Detroit, MI


Health Sciences Institutional Review Board
University of Pittsburgh
Pittsburgh, PA

95S-0158

SUP 22

If you have any comments or questions regarding this submission, please do not hesitate to contact me at (425) 415-2297.

Sincerely,

A handwritten signature in black ink, reading "Jeff Hesselberg". The signature is fluid and cursive, with a long horizontal stroke extending to the right.

Jeff Hesselberg, M.B.A.
Associate Director, Regulatory Affairs



Advertisement ran 9/29/99-10/5/99 in the MetroTimes

Advertisement ran 12/17/99 in the Detroit News

Advertisement ran 12/17/99 in the Detroit Free Press

Advertisement ran 9/29/99-10/5/99 in the Michigan Chronicle

Trauma Study Results

Henry Ford Hospital recently participated in a research study to evaluate an investigational drug that may help severely injured patients. The investigational drug being tested is called Hu23F2G (LeukArrest). The research study is sponsored by ICOS Corporation (Bothell, Washington). Hu23F2G acts on the white blood cells and may prevent them from causing damage to the body's major organs following trauma. In order to determine the safety and effectiveness of this new drug, researchers studied 150 trauma victims at 11 trauma centers throughout the United States. In the clinical trial, some patients received Hu23F2G along with standard care and some patients received the standard care for severe injury alone.

Patients were enrolled into the study in one of three ways. First, patients gave their own informed consent if they were able. Second, if a patient were unable to give consent, then upon arrival in the emergency department the hospital staff attempted to reach a family member. If this was successful, the family was asked to provide informed assent. Third, if a family member was not located within three hours, the patient was enrolled under the Food and Drug Administration (FDA) regulations waiving the requirement to obtain an informed consent. The effort to locate and inform family continued after the patient had been enrolled into the study under the FDA regulations waiving the requirement to obtain informed consent. Use of the FDA regulations waiving the requirement to obtain an informed consent in this study was approved by the FDA and the Henry Ford Hospital Human Rights Committee, which is charged with ethical oversight of patient research at Henry Ford Hospital.

Enrollment into this study was completed on January 26, 1999. Across the entire study, 14% of patients signed their own consent, 53% had a family member provide informed assent and 33% were enrolled with waiver of informed consent. At Henry Ford Hospital, 3 patients were enrolled into the study from 11/6/98 to 12/5/98. No patients signed their own consent, 3 had family member provide informed assent, and no patients were enrolled with a waiver of informed consent.

In this study, the average patient age was 36 years old, males were enrolled about twice as often as females. The majority of the patients were Caucasian (58%), followed by African American (25%) and other races (17%). At Henry Ford Hospital the average patient age was 29 years old, 3 males and 0 females were enrolled. The majority of the patients were African American (66%) followed by other races (34%).

Preliminary analysis of the study has been performed. Hu23F2G appeared to be safe in this patient population. A total of 11 patients (7%) died in the study. The death rate was 10% in patients that received standard care alone and 6% in patients who received Hu23F2G. Although the endpoints that the study was designed to measure were no different between the patients that received standard of care and the patients that received Hu23F2G along with standard of care, there was a suggestion that those patients who received the higher dose of Hu23F2G had decreased heart and lung failure compared with those patients who received standard care only. Further analyses of the data are underway.

Any questions about this study should be directed to Frank R. Lewis, MD at (313) 876-3152.



Advertisement ran 11/18/99 in the New Castle News (New Castle, PA)

Advertisement ran 11/18/99 in The Vindicator (Youngstown, PA)

Advertisement ran 11/18/99 in the Pittsburgh Post Gazette

Advertisement ran 11/18/99 in the Pittsburgh Tribune Review

Advertisement ran 11/18/99 in the Clarion News (Clarion, PA)

Advertisement ran 11/18/99 in the Erie Daily News (Erie, PA)

Trauma research study results

UPMC Health System recently participated in a research study to evaluate an investigational drug that may help severely injured patients. The investigational drug being tested is called Hu23F2G (LeukArrest). The research study is sponsored by ICOS Corporation (Bothell, Wa.). Hu23F2G acts on the white blood cells and may prevent them from causing damage to the body's major organs following trauma. In order to determine the safety and effectiveness of this new drug, researchers studied 150 trauma victims at 11 trauma centers throughout the United States. In the clinical trial, some patients received Hu23F2G along with standard of care, and some patients received the standard of care for severe injury alone.

Patients were enrolled into the study in one of three ways. First, patients gave their own informed consent if they were able. Second, if a patient was unable to give consent, then upon arrival in the emergency department, the hospital staff attempted to reach a family member. If this was successful, the family was asked to provide informed assent. Third, if a family member was not located within three hours, the patient was enrolled under the Food and Drug Administration (FDA) regulations waiving the requirement to obtain an informed consent. The effort to locate and inform family continued after the patient had been enrolled into the study under the FDA regulations waiving the requirement to obtain an informed consent. Use of the FDA regulations waiving the requirement to obtain an informed consent in this study was approved by the FDA and the University of Pittsburgh Institutional Review Board, which is charged with ethical oversight of patient research at UPMC Health System.

Enrollment into this study was completed on Jan. 26, 1999. Across the entire study, 14% of patients signed their own consent, 53% had a family member provide informed assent, and 33% were enrolled with waiver of informed consent. At UPMC Health System, nine patients were enrolled into the study from July 3, 1998, to Dec. 17, 1998. Two patients signed their own consent, one had a family member provide informed assent, and six patients were enrolled with a waiver of informed consent.

In this study, the average patient age was 36 years old, and males were enrolled about twice as often as females. The majority of the patients were Caucasian (58%), followed by African American (25%) and other races (17%). At UPMC Health System, the average patient age was 40 years old; eight males and one female were enrolled. 100% of the patients enrolled were Caucasian.

Preliminary analysis of the study has been performed. Hu23F2G appeared to be safe in this patient population. A total of 11 patients (7%) died in the study. The death rate was 10% in patients who received standard of care alone and 6% in patients who received Hu23F2G. Although the endpoints the study was designed to measure were no different for the patients who received standard of care and the patients who received Hu23F2G along with standard of care, there was a suggestion that those patients who received the higher dose of Hu23F2G had decreased heart and lung failure compared to those patients who received standard of care only. Further analyses of the data are under way.

Any questions about this study should be directed to Andrew Peitzman, MD. at (412) 648-9863.



UPMC HEALTH SYSTEM

FedEx USA Airbill

FedEx
Tracking
Number

805616859941

0210

SPL12
FedEx Retrieval Code

1 From
Date 02/04/00 Sender's FedEx Account Number 1316-6207-6

Sender's Name Jeff Hesselberg Phone (425) 485-1900

Company ICOS CORPORATION

Address 22021 20TH AVE SE

Dept./Floor/Suite/Room

City BOTHELL

State WAZIP 98021

2 Your Internal Billing Reference Information

3 To
Recipient's Name Food + Drug Administration Phone (301) 827-6860

Company Docket's Management Branch Attn: Docket No. 755-0158

Address 5630 Fishers Lane, Room 1061

To "HOLD" at FedEx location, print FedEx address here

Dept./Floor/Suite/Room

City Rockville

State MDZIP 20852

For HOLD at FedEx Location check here


☐ **HOLD Weekday** 31
(Not available with
FedEx First Overnight)

☐ **HOLD Saturday**
(Available for FedEx Priority Overnight
and FedEx 2Day only)

For WEEKEND Delivery check here

☐ **Saturday Delivery** 33
(Available for FedEx Priority
Overnight and FedEx 2Day only)

☐ **NEW Sunday Delivery**
(Available for FedEx
Priority Overnight only)



805616859941

4a Express Package Service Packages under 150 lbs.
☒ **FedEx Priority Overnight** Next business morning
☐ **FedEx Standard Overnight** Next business afternoon
☐ **FedEx First Overnight** Earliest next business morning delivery to select locations (Higher rates apply)
☐ **FedEx 2Day** Second business day
☐ **FedEx Express Saver** Third business day
FedEx Latex Rate not available. Minimum charge. One pound rate.

4b Express Freight Service Packages over 150 lbs.
☐ **FedEx Overnight Freight** Next business morning
☐ **FedEx 2Day Freight** Second business day
☐ **FedEx Express Saver Freight** Third business day
Call for delivery schedule. See back for detailed descriptions of freight services.

5 Packaging ☐ **FedEx Pak** ☐ **FedEx Pak** ☒ **FedEx Box** ☐ **FedEx Tube**
Declared value limit \$500

6 Special Handling
Does this shipment contain dangerous goods? ☐ No ☐ Yes ☐ Yes ☐ Yes
☐ **Dry Ice** (Dry ice, 3.145 lbs. max) ☐ **Cargo Aircraft Only**

7 Payment
Bill to: ☒ **Sender** ☐ **Recipient** ☐ **Third Party** ☐ **Credit Card** ☐ **Other**
Section 1 will be billed. Enter FedEx Account No. or Credit Card No.

FedEx Account No.
Credit Card No.

Total Packages 1 Total Weight 2 Total Charge \$

When declaring value, use actual value or declared value, whichever is greater. SERVICE CONDITIONS DECLARED VALUE AND LIMIT OF LIABILITY. See back for details.

8 Release Signature

Signature of authorized person to receive this shipment. (Signature required for all shipments.)

321

W/C
Rev. Co.
Part

004835769 4